Translate page

GoldmanPrize medal RGB reduc

Recognising extraordinary work in CML
Nominate now for the iCMLf Prizes

In these challenging times of the COVID-19 pandemic, it is more important than ever to direct all our efforts to provide the best possible care for patients with CML around the globe and to continue to work towards a cure for CML.

With this in mind, we continue with our tradition to recognise and reward personal contributions and outstanding achievements to our understanding of the biology of CML and to improving the management of patients with CML globally.

Since the first iCMLf Rowley Prize was awarded to Professor Brian Druker in 2009, we have honoured 26 scientists and clinicians with the three specific iCMLf Prizes.

Who would you like to see awarded the iCMLf prizes next year?

The iCMLf Prizes


iCMLf Rowley Prizejanetrowley-head-mod-small 

The Rowley Prize is awarded each year by the iCMLf to an individual who has made an outstanding lifetime contribution to our understanding of the biology of CML. The Rowley Prize was awarded for the first time in 2009 to Dr Brian Druker, followed by Dr Moshe Talpaz (2010), Dr John Goldman (2011), Dr George Q Daley (2012), Dr Connie Eaves (2013), Dr. Owen Witte (2014), Dr Rick Van Etten (2015), Professors John Groffen and Nora Heisterkamp (2016), Professor Tessa Holyoake (2017), Professor Nick Cross (2018), Professor Michael Deininger (2019) and Professor Ravi Bhatia in 2020. 

Dr Janet Rowley kindly gave the iCMLf permission to name this prestigious award in her honour. Prior to her death in December 2013, Dr Rowley was the Blum-Riese Distinguished Service Professor of Medicine, Molecular Genetics and Cell Biology and Human 
Genetics at the University of Chicago. In 1973 she made a seminal discovery in CML when she used newly developed chromosome banding techniques to show that the Philadelphia chromosome is formed by a translocation between chromosomes 9 and 22. This discovery led to the eventual identification of the fusion gene BCR-ABL and ultimately to the development of targeted inhibitors of this leukemia-specific oncoprotein. This is one of many major contributions made by Dr Rowley and her team to our understanding of the molecular biology of leukemia and other cancers. She was recently awarded the Presidential Medal of Freedom, the highest civilian honour awarded in the USA.


iCMLf Goldman Prizejohn goldman

The iCMLf Goldman Prize complements the Rowley Prize as a clinical equivalent by recognising lifetime contributions to the management of patients with CML. This award has been created in memory of the late iCMLf chair, John Goldman, to honour his commitment to clinical excellence in treating CML. John Goldman was an outstanding scientist with a worldwide recognition and a leading figure in CML research. During his career of over 40 years he made major contribution to the understanding of the biology and the treatment of CML. He made seminal contributions to a variety of breakthroughs in CML research particularly in the field of stem cell transplantation, in the clinical development of new therapies and in the advancements of diagnostics. He was the first to demonstrate the presence of stem cells in the peripheral blood of CML patients and their potential role in autografting patients with CML. He also pioneered allogeneic stem cell transplant for CML in Europe. John Goldman played a distinctive and visionary role for the iCMLf as one of its co-founders and sitting chair at the time of his death. The Goldman Prize was awarded for the first time in 2014 to Professor Rüdiger Hehlmann, he was followed by Michele Bacarrani (2015), Professor Hagop Kantarjian (2016), Professor Tim Hughes (2017), Professor Jorge Cortes (2018), Professor François-Xavier Mahon (2019) and Professor Jane Apperley in 2020.


iCMLf Prize

In 2015 the iCMLf introduced a new prize. The iCMLf Prize is awarded annually by the iCMLf to recognise outstanding contributions to the improvement of CML treatment in the emerging economic regions. The iCMLf Prize was formerly named the ERSAP (Emerging Regions Support and Partnership Prize) and was first awarded in 2015 to Pat Garcia-Gonzalez, CEO of The Max Foundation. She was followed by Associate Professor Susan Branford in 2016, Professor Jerry Radich (2017), Professor Hemant Malhotra (2018), Dr Carolina Pavlovsky (2019) and Dr Sabira Kurtovic in 2020. 


RS18632 Ravi Bhatia 2 KopieThe 2020 iCMLf Rowley Prize is awarded to Professor Ravi Bhatia

We are delighted to announce that this year Professor Ravi Bhatia, Director of the University of Alabama Division of Hematology-Oncology and Deputy Director of the O’Neal Comprehensive Cancer Center at the University of Alabama in Birmingham, USA, joins the long line of internationally renowned scientists awarded the iCMLf Rowley Prize. This annual prize awarded by the International CML Foundation recognises outstanding contributions to the understanding of the biology of CML.

‘Ravi Bhatia is a global leader in leukemia research who has made fundamental discoveries about the nature of the leukemic stem cell in CML. These discoveries are leading to promising therapeutic developments. He is also a generous and inspirational mentor and educator. Ravi is a very worthy winner of the Rowley Prize for 2020.’
(Timothy Hughes, Chairman of the iCMLf)

DSC04074The 2020 iCMLf Goldman Prize is awarded to Professor Jane Apperley

The iCMLf is pleased to announce the winner of the 2020 Goldman Prize. Professor Jane Apperley, Chair of the Centre for Haematology at Imperial College, London, UK will receive her Goldman medal during the 2020 John Goldman meeting on CML in October. The annual Goldman Prize, awarded in honour of Professor John Goldman, acknowledges outstanding contributions to the management of patients with CML. Professor Apperley receives the prize in recognition of her exceptional reputation as a clinical academic and her many years of expertise in CML and blood and bone marrow transplantation.

"Jane has been one of the leaders in CML research for many years. She has helped us not only develop better therapies for patients with CML, but with thorough, thoughtful and innovative research and analysis, understand the best way to manage patients incorporating all known variables and even helping us think of new variables that play a role. She has always kept a critical but balanced view of the data and performed innovative and groundbreaking research. Jane and her group have been leaders in CML research for many years and her contributions make her a very deserving recipient of this award. And even more fitting having worked with John for so many years.”
(Professor Jorge Cortes, Georgia Cancer Center, Augusta University)

02 DSC 3070 KopieThe 2020 iCMLf Prize is awarded to Dr Sabira Kurtovic
(Bosnia and Herzegovina)

The iCMLf awards the 2020 iCMLf Prize to Dr Sabira Kurtovic, a hematologist at the Clinical Centre of the University of Sarajevo, Bosnia and Herzegovina.

This iCMLf Prize recognises outstanding contributions to the improvement of CML treatment under the challenging conditions of low- and middle-income countries with unequal access to monitoring and treatment. Dr Kurtovic is awarded the iCMLf Prize for her tireless work to ensure that patients with CML in Bosnia and Herzegovina receive the best possible care and have access to treatment with tyrosine kinase inhibitors (TKIs).

"I am thrilled and delighted that Dr Kurtovic will receive the 2020 iCMLf Prize. She has demonstrated a humanitarian spirit and drive through war and beyond, managing always to keep patient welfare at the forefront. Having worked with her I know first hand her dedication, intelligence, and compassion."
(Professor Jerry Radich, Fred Hutchinson Cancer Research Centre)

Michael DeiningerThe 2019 Rowley Prize is awarded to Professor Michael Deininger

Michael W. Deininger, Professor of Internal Medicine and Adjunct Professor of Oncological Sciences at the Huntsman Cancer Institute, University of Utah, Salt Lake City, has been awarded the 2019 iCMLf Rowley Prize. The Rowley Prize is awarded to celebrate people who have made outstanding lifetime contributions to the understanding of the biology of CML.

Michael Deininger receives the prize in recognition of his involvement in researching the biology of CML that has contributed to the establishment of tyrosine kinase inhibitor (TKI) based therapies in CML and has significantly transformed the way CML is being diagnosed, treated and monitored today. As a clinician-scientist with a translational research focus, Professor Deininger has been researching the biology and therapy of CML for more than 20 years now constantly aiming to develop new and more effective therapies and strategies to prevent drug resistance.